XML 43 R32.htm IDEA: XBRL DOCUMENT

Debt - (Tables)

6 Months Ended

Jun. 30, 2025

Debt Instrument, Redemption [Line Items]

Summary of liability for sale of future royalties


		Six Months Ended June 30,
Liability for sale of future royalties- (current and noncurrent)		2025
Beginning balance as of December 31, 2024		$	2,081,776
Less: Non-cash royalty revenue payable to Royalty Pharma			(85,099)
Plus: Non-cash interest expense recognized			99,329
Ending balance		$	2,096,006
Effective interest rate as of June 30, 2025			9.3%

2026 Convertible Notes

Debt Instrument, Redemption [Line Items]

Summary of convertible notes



		June 30, 2025			December 31, 2024
Principal		$	287,500		$	287,500
Less: Debt issuance costs			(1,487)			(2,088)
Net carrying amount		$	286,013		$	285,412

Summary of interest expense recognized related to the Convertible Notes


			Three Months Ended June 30,						Six Months Ended June 30,
		2025			2024			2025			2024
Contractual interest expense		$	1,067		$	1,066		$	2,135		$	2,142
Amortization of debt issuance costs			301			295			601			591
Total		$	1,368		$	1,361		$	2,736		$	2,733
Effective interest rate			1.9	%		1.9	%		1.9	%		1.9	%